| Literature DB >> 36247670 |
Mamaru Bitew Alem1, Tadewos Damena1, Tegene Desalegn1, Moses Koobotse2, Rajalakshmanan Eswaramoorthy3, Kennedy J Ngwira4, Japheth O Ombito5, Matshediso Zachariah2, Taye B Demissie5.
Abstract
Herein, we report the synthesis of mixed-ligand Cu(II) complexes of metformin and ciprofloxacin drugs together with 1,10-phenanthroline as a co-ligand. The synthesized complexes were characterized using different spectroscopic and spectrometric techniques. In vitro cytotoxic activity against human breast adenocarcinoma cancer cell line (MCF-7) as well as antibacterial activity against two gram-negative and two gram-positive bacterial strains were also investigated. The analyses of the experimental results were supported using quantum chemical calculations and molecular docking studies against estrogen receptor alpha (ERα; PDB: 5GS4). The cytotoxicity of the [Cu(II) (metformin) (1,10-phenanthroline)] complex (1), with IC50 of 4.29 µM, and the [Cu(II) (ciprofloxacin) (1,10-phenanthroline)] complex (2), with IC50 of 7.58 µM, were found to be more effective than the referenced drug, cisplatin which has IC50 of 18.62 µM against MCF-7 cell line. The molecular docking analysis is also in good agreement with the experimental results, with binding affinities of -7.35, -8.76 and -6.32 kcal/mol, respectively, for complexes 1, 2 and cisplatin against ERα. Moreover, complex 2 showed significant antibacterial activity against E. coli (inhibition diameter zone, IDZ, = 17.3 mm), P. aeruginosa (IDZ = 17.08 mm), and S. pyogen (IDZ = 17.33 mm), at 25 μg/ml compared to ciprofloxacin (IDZ = 20.0, 20.3, and 21.3 mm), respectively. Our BOILED-egg model indicated that the synthesized metal complexes have potentially minimal neurotoxicity than that of cisplatin.Entities:
Keywords: BOILED-egg; Cu(II) complexes; DFT; MCF-7; antibacterial activity; cytotoxicity; molecular docking
Year: 2022 PMID: 36247670 PMCID: PMC9557196 DOI: 10.3389/fchem.2022.1028957
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.545
SCHEME 1The synthesis procedure of the two Cu(II) complexes (1 and 2).
FIGURE 1FTIR Spectra of the synthesized metal complexes 1 (top) and 2 (bottom).
Vibrational frequencies (experimental/calculated) of selected functional groups of the ligands and their metal complexes.
| Compound | Selected vibrational frequencies (cm−1) | |||||||
|---|---|---|---|---|---|---|---|---|
| ν(OH) | ν(C=O) | ν(N=C) | ν(N-H) | ν(NH2) | ν(N=C) | M-O | M-N | |
| Cip | 3,520/- | 1710/1,694 | ||||||
| 1,608/1529c | — | 3,444/3,406 | — | — | — | — | ||
| Met | — | — | 1,647/1,643 | 3,430/3,520 | 3,423/3,569 | — | — | |
| 1,10-phen | 3,437 | — | — | — | — | 1,587/1,549 | — | — |
|
| — | — | 1,626/1,680 | 3,394/3,510 | 3,316/3,529 | 1,523/1,503 | — | 544/492, 430/416 |
|
| — | 1,640/1,561 | — | 3,419/3,442 | — | 1,615/1,579 | 509/452 | 422/423 |
a
b
Metformin N=C bond, 1,10-phenathroline N=C bond, c-quinolone C=O.
Temperature range values for decomposition and corresponding weight loss values.
| Decomposition | Mass loss (%) | Interpretation | ||
|---|---|---|---|---|
| Temp. (°C) | Obsd | Calcd | ||
|
| 100–200 | 11.68 | 11.74 | loss due to three lattice water molecules |
| 230–340 | 32.34 | 2.41 | lost its two coordinated water molecules and metformin moiety (2H2O+ C4H9N4) groups | |
| 345–570 | 11.44 | 11.52 | release of the C3H3N organic moiety | |
| 580–750 | 30.42 | 30.62 | release of the C9H5N2 organic moiety | |
|
| 90–225 | 13.94 | 13.96 | the release of C4H9N2 molecules |
| 230–310 | 8.81 | 8.93 | lost its two chlorine and fluorine molecules moiety (Cl + F) | |
| 320–550 | 25.22 | 25.30 | release of the C11H8N organic moiety | |
| 560–700 | 20.81 | 20.84 | release of the C9H5N organic moiety | |
FIGURE 2TGA (blue) and DTA (red) curves for complexes 1 and 2.
FIGURE 3UV-Vis spectra of the synthesized mixed ligand metal complex 1.
FIGURE 4UV-Vis spectra of 2 mixed ligand metal complexes.
Quantum chemical descriptor analysis of the ligands and the synthesized metal complexes.
| CPD | HOMO | LUMO | Eg | Χ | μ |
| σ | ω |
| Dipole Moment |
|---|---|---|---|---|---|---|---|---|---|---|
|
| −6.440 | −0.452 | 5.988 | 3.446 | −3.446 | 2.994 | 0.167 | 1.983 | 0.504 | 5.752 |
|
| −6.690 | −1.935 | 4.755 | 4.313 | −4.313 | 2.377 | 0.210 | 3.912 | 0.256 | 5.192 |
|
| −6.155 | −2.059 | 4.096 | 4.107 | −4.107 | 2.048 | 0.244 | 4.118 | 0.243 | 15.128 |
|
| −4.630 | −2.335 | 2.295 | 3.482 | −3.482 | 1.148 | 0.436 | 5.283 | 0.189 | 9.215 |
|
| −6.268 | −2.616 | 2.886 | 4.442 | −4.442 | 1.826 | 0.274 | 5.402 | 0.185 | 13.759 |
FIGURE 5HOMO—LUMO distribution and band gap energy of the synthesized metal complexes.
FIGURE 6Mean inhibition zone diameter of mixed-drug metal complexes 1 and 2 and ciprofloxacin in mm at 25 and 50 µg/ml.
FIGURE 7Cell viability of MCF-7 cancer cell line against complexes 1 and 2 and cisplatin.
In vitro cytotoxic activity of complexes 1 and 2 against MCF-7 cell line.
| Compound | IC50 ( |
|---|---|
|
| 4.29 ± 0.12 |
|
| 7.58 ± 0.10 |
|
| 18.62 ± 3.56 |
FIGURE 8BOILED egg model of the ligands (1,10-Phenanthroline, Ciprofloxacin, and metformin), 1, 2 and Cisplatin.
FIGURE 9The (A) 3D and (B) 2D presentations of the binding interactions of complexes 1 and 2 against estrogen receptor alpha (ERα; PDB: 5GS4).
Molecular docking scores and the corresponding prominent residual amino acid interactions of the complexes against estrogen receptor alpha (ERα; PDB:5GS4).
| CPDS | Rmsd | Binding energy (Kcal/Mol) | Inhibition constant ( | H (µM)-Bonding with | Π-Sigma/Π-Alkyl | Van der waals |
|---|---|---|---|---|---|---|
|
| 0.10 | −7.35 | 4.12 | Leu387 | Leu525, Ala350, Ile424 | Phe404, Leu349, Leu428 |
|
| 0.05 | −8.76 | 0.38 | Glu542, Val376 | Leu372, Ile358, Leu379 | Lys362, Phe367, Glu380 |
|
| 0.39 | −6.32 | 23.42 | Ser468, Asp374 | Lys467f | Thr371, Glu471 |